 |
|
IL-2/Lptn gene-modified allogeneic neuroblastoma tumor cell vaccine
A cancer vaccine consisting of allogeneic neuroblastoma tumor cells have been genetically modified to secrete the human cytokine interleukin-2 (IL-2) and the human chemokine lymphotactin (Lptn) with potential immunostimulating and antineoplastic activities. Upon administration, IL-2 and Lptn are secreted by the IL-2/Lptn gene-modified allogeneic neuroblastoma tumor cell vaccine, potentially enhancing the cytotoxic T lymphocyte (CTL) response elicited by vaccine neuroblastoma tumor-associated antigens (TAAs) against host neuroblastoma tumor cells. Produced by activated progenitor T cells, Lptn belongs to the C chemokine subfamily and is a potent chemotactic factor for lymphocytes; IL-2 stimulates natural killer (NK) cells and may enhance a vaccine-elicited CTL immune response against tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | interleukin-2/lymphotactin gene-modified allogeneic neuroblastoma tumor cell vaccine
SJNB-JF-IL2 and SJNB-JF-Lptn cells and SKNLP unmodified neuroblastoma cell lines | | |
| Previous: | IGF-1R antagonist BMS-754807, IGF-1R inhibitor OSI-906, IH636 grape seed proanthocyanidin extract, IL-2 plasmid DNA/lipid complex, IL-2 recombinant fusion protein ALT-801 | | Next: | iloprost, Ilotycin, Imagent, imatinib mesylate, imexon |
|
|
